According to the National Institute of Health, one in every twenty Americans over the age
of 50 years old suffers from peripheral artery disease (PAD). PAD is a manifestation of
systemic atherosclerosis and is specifically characterized by atherosclerotic blockages
of the arteries in the legs. This results in claudication, a commonly experienced leg
pain and immobility due to occlusion of the blood vessels. This pain reduces the amount
of physical activity PAD patients can participate in, which can be detrimental to the
patient, as it can lead to more systemic issues such as coronary artery disease, heart
failure, and metabolic disorders, as well as amputation and death. These periods of
occlusion are thought to be caused by endothelial dysfunction in the peripheral arteries
leading to the legs, which results in an inability to produce nitric oxide (NO), a potent
vasodilator which has been shown to be decreased in patients with PAD. Patients with PAD
have also shown higher levels of systemic and skeletal muscle inflammation due to the
impaired oxygen transfer capacity of these blood vessels. This inflammation leads to an
increase in reactive oxygen species (ROS), which reduce the bioavailability of NO and are
closely linked to the vascular dysfunction in PAD. Furthermore, mitochondria, a major
cellular component that is responsible for the regulation between levels of production of
ROS and antioxidants have shown to be altered in patients with PAD, which may lead to
impaired oxygen transfer and utilization capacity, ultimately resulting in claudication,
impaired functional capacity and reduced physical activity. Nitric oxide has been shown
to be an important regulator within the cardiovascular system, responsible for regulation
of blood flow, blood pressure and vascular growth. Additionally, many cardiovascular
diseases have been shown to be highly associated with a reduced bioavailability of NO and
a positively associated increase in ROS. These heightened levels of ROS not only reduce
the availability of NO, but they may also cause cellular damage within the muscle and
cardiovascular system. This combination of a reduced ability of the peripheral blood
vessels to dilate due to decreased levels of NO, with a concomitant increased level of
inflammation due to higher ROS levels could be extremely detrimental to patients with
PAD, as the limited oxygen delivery to skeletal muscles could ultimately result in
claudication and reduced physical ability. However, this reduced oxygen delivery and
utilization may be able to be improved as previous studies have suggested that
tetrahydrobiopterin (BH4), is an important cofactor responsible for NO production.
Furthermore, recent studies have shown that endothelial BH4 levels are associated with
the vascular pathophysiological response to hypoxia, as it directly mediates endothelial
nitric oxide synthase regulation and reduces superoxide production. Additionally, acute
administration of BH4 was shown to improve vascular function, specifically, endothelial
mediated vasodilatory function, in patients with systemic vascular and coronary disease,
as well as six minute walking distances in patients with hypertension. Therefore, the
purpose of this proposed study will be to examine the effects of BH4 on vascular
function, oxidative stress and leg performance in patients with PAD. The findings of this
study may help to develop a new clinical therapy for patients with PAD. In this study we
will examine endothelial function via flow-mediated dilation, blood flow in the femoral
and popliteal arteries with a doppler ultrasound, leg skeletal muscle oxygenation with
near-infrared spectroscopy, oxidative stress via blood samples and leg function by
conducting a endurance test on an isokinetic dynamometer in 10 class-1 or class-2 PAD
patients. We will use 5 mg/kg of BH4 obtained from Biomarin Pharmaceutical Industries in
a 1:1 randomized, double-blinded, cross-over design with a 2-week washout period between
testing days.